MIR96-IN-1


Cat. No.:	HY-15843		
CAS No.:	1311982-88-3		
Molecular Formula:	C ₃₃ H ₄₈ N ₈ O ₂		
Molecular Weight:	588.79		
Target:	MicroRNA; Apoptosis		
Pathway:	Epigenetics; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year

SOLVENT & SOLUBILITY

* "≥" means soluble, Preparing Stock Solutions	* "≥" means soluble, but saturation unknown.					
		Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	1.6984 mL	8.4920 mL	16.9840 mL	
	5 mM	0.3397 mL	1.6984 mL	3.3968 mL		
	10 mM	0.1698 mL	0.8492 mL	1.6984 mL		
	Please refer to the solubility information to select the appropriate solvent.					
ı Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution					
	 Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution 					

BIOLOGICAL ACTIVITY					
BIOLOGICAL ACTIVITY					
Description	MIR96-IN-1 targets the Drosha site in the miR-96 (miRNA-96, microRNA-96) hairpin precursor, inhibiting its biogenesis, derepressing downstream targets, and triggering apoptosis in breast cancer cells. MIR96-IN-1 binds to RNAs with K _d s of 1.3, 9.4, 3.4, 1.3 and 7.4 μM for RNA1, RNA2, RNA3, RNA4 and RNA5, respectively ^[1] . MIR96-IN-1 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.				
In Vitro	MIR96-IN-1 (Compound 1) selectively inhibits production of mature miR-96 and triggers apoptosis in breast cancer cells at micromolar concentrations ^[1] .				





Product Data Sheet

MIR96-IN-1 (Compound 3) binds a UU loop in miR-96 and inhibits its biogenesis^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Sai Pradeep Velagapudi, et al. Design of a small molecule against an oncogenic noncoding RNA. Proc Natl Acad Sci U S A. 2016 May 24;113(21):5898-903.

[2]. Christopher L Haga, et al. Small Molecule Inhibition of miR-544 Biogenesis Disrupts Adaptive Responses to Hypoxia by Modulating ATM-mTOR Signaling. ACS Chem Biol. 2015 Oct 16;10(10):2267-76.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA